



Collaboration Overview



Introduction

Ximbio

- World's largest non-profit organisation dedicated to commercial use of life science laboratory research tools, reagents, and materials
- Wholly owned subsidiary of Cancer Research UK
- Partnerships with more than 150 Technology Transfer Offices, over 2000 researchers and more than 200 life science companies worldwide

Partnership with Charles University

- Sale of compounds and other research tools developed at CUNI through Ximbio's portfolio (Ximbio.com)
- Ximbio pays CUNI 60 % of revenue generated by offered compounds
 - Researchers are entitled to up to 55 % of the received sum based on Rector's Directive No. 46/2018
- Requires minimum effort on researcher's side
 - Preparation of compounds in required commercial amounts takes place in Ximbio's labs based on provided preparation protocols
- Opportunity to repurpose compounds and tools developed in research projects and with no further use
 - Interest in compounds and tools both with and without IP protection

Ximbio's Portfolio







Cell Lines



Mouse Models



Small Molecules



Vectors



Peptides and Proteins



Zebrafish



Recombinant Antibodies



Lab Consumables



Bacteria

What Is Required to Provide?

- Structure or any other form of characterisation of offered research tools
- Preparation protocols

- Optional:
 - Small samples for analyses
 - Can be crude (Ximbio will purify them themselves)
 - · Data from analyses, biological testing, etc.
 - Information on original intended use and other potential applications
 - Information on expected biological activity
 - Other available relevant documentation

Contact



Dr. Antonín Králík

Analyst and Patent Specialist

Phone: +420 771 134 090

E-Mail: kralik@cuip.cz